Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Calliditas Therapeutics Ab ADR (CALT)

Calliditas Therapeutics Ab ADR (CALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Calliditas Therapeutics Ab ADR KUNGSBRON 1 C8 STOCKHOLM V7 11122 SWE

www.calliditas.se P: 46-0-841-130-05

Description:

Calliditas Therapeutics AB is a specialty pharmaceutical company. It is focused on developing pharmaceutical products for patients with a significant unmet medical need. The compnay's lead candidate consist Nefecon. Calliditas Therapeutics AB is based in Stockholm, Sweden.

Key Statistics

Overview:

Market Capitalization, $K 551,115
Enterprise Value, $K 547,895
Shares Outstanding, K 29,790
Annual Sales, $ 113,810 K
Annual Net Income, $ -43,960 K
Last Quarter Sales, $ 42,450 K
Last Quarter Net Income, $ -1,730 K
EBIT, $ -35,180 K
EBITDA, $ -35,180 K
60-Month Beta 1.50
% of Insider Shareholders 2.20%
% of Institutional Shareholders 2.83%
Float, K 29,135
% Float 97.80%
Short Volume Ratio 0.27

Growth:

1-Year Return -26.99%
3-Year Return -37.50%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.06 on 02/21/24
Latest Earnings Date 05/21/24
Earnings Per Share ttm -1.64
EPS Growth vs. Prev Qtr 89.66%
EPS Growth vs. Prev Year -500.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CALT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 63.39
Price/Earnings to Growth N/A
Return-on-Equity % -104.48%
Return-on-Assets % -26.75%
Profit Margin % -38.63%
Debt/Equity 2.81
Price/Sales 4.77
Price/Cash Flow N/A
Price/Book 17.65
Book Value/Share 1.06
Interest Coverage -4.44
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar